|
Volumn 4, Issue 3, 2008, Pages 171-173
|
Commentary on "A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium"
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
AMYLOID BETA PROTEIN;
AMYLOID BETA PROTEIN ANTIBODY;
BETA SECRETASE INHIBITOR;
CLOPIDOGREL;
GAMMA SECRETASE INHIBITOR;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
HYPOCHOLESTEROLEMIC AGENT;
NOOTROPIC AGENT;
ROFECOXIB;
ROSIGLITAZONE;
ALZHEIMER DISEASE;
ARTICLE;
CLINICAL RESEARCH;
COGNITIVE DEFECT;
CORONARY ARTERY DISEASE;
COST CONTROL;
DEMENTIA;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TARGETING;
HEALTH CARE COST;
HEART INFARCTION;
HIGH RISK POPULATION;
HUMAN;
HYPOTHESIS;
NERVE DEGENERATION;
PATHOPHYSIOLOGY;
POSITRON EMISSION TOMOGRAPHY;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
SENILE PLAQUE;
SYMPOSIUM;
|
EID: 43649085939
PISSN: 15525260
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jalz.2008.03.008 Document Type: Note |
Times cited : (2)
|
References (11)
|